This is a working overview of Drug affinity complex, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-30. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
== In popular culture == The game of Tetris is a puzzle game in which blocks of 4 are adsorbed onto a surface during game play. Scientists have used Tetris blocks "as a proxy for molecules with a complex shape" and their "adsorption on a flat surface" for studying the thermodynamics of nanoparticles.
In June 2026, Trump issued Executive Order 14409, "Promoting Advanced Artificial Intelligence Innovation and Security", directing agencies to strengthen federal cybersecurity, expand the use of AI-enabled defensive tools, establish a voluntary framework for secure deployment of frontier AI models, and prioritize enforcement against AI-enabled cybercrime. The framework for secure deployment outlined by the order includes the establishment of a "covered frontier model" designation, to be applied by the Director of the NSA in accordance with a "classified benchmarking process" to assess the capabilities of AI models. AI developers may voluntarily submit newly developed models to the federal government to determine if they qualify as "covered frontier models" and to provide the federal government with exclusive access for up to thirty days before models are released more broadly. In September 2026, Trump announced an AI Force, to be led by an AI Czar. Senator Bernie Sanders and Representative Greg Casar introduced the "Ban Artificial Superintelligence Act" in the Senate, which would ban the creation of artificial superintelligence, referring to systems which exceed human abilities on most tasks or which are capable of destroying humanity.
== Applications == The remarkable stability of cyclotides means that they have an exciting range of potential applications centred on either their intrinsic biological activities or the possibility of using the CCK motif as a scaffold for stabilizing biologically active epitopes. Interest in these has recently intensified with the publications of a chemical methodology capable of synthetically producing cyclotides with high yields, and the amenability of the CCK framework to amino-acid substitutions. But for molecules to be useful in a therapeutic setting they require useful biopharmaceutical characteristics such as resistance to proteolysis and membrane permeability. The membrane interactive surface area and moment of the cyclotides are determinants in the prediction of their biological activities. A recent study on related cystine knot proteins as drug candidates showed that cystine knots do permeate well through rat small intestinal mucosa relative to non-cystine knot peptide drugs such as insulin and bacitracin. Furthermore, enzymatic digestion of cystine knot peptide drugs was associated with only a few proteases and it was suggested that this limitation may be overcome by mutating out particular cleavage sites. Thus, certain cystine knot proteins satisfy the basic criteria for drug delivery and represent exciting novel candidates as scaffolds for peptide drug delivery.
Sources: en.wikipedia.org
Take white (Yemeni) alum, dissolve it and purify it by filtration. Then distil (green?) vitriol with copper-green (the acetate), and mix (the distillate) with the filtered solution of the purified alum, afterwards let it solidify (or crystallise) in the glass beaker. You will get the best qalqadis (white alum) that may be had. In an anonymous Latin work variously attributed to Aristotle (under the title Liber Aristotilis, 'Book of Aristotle'), to al-Razi (under the title Lumen luminum magnum, 'Great Light of Lights'), or to Ibn Sina, the author speaks of an 'oil' (oleum) obtained through the distillation of iron(II) sulfate (green vitriol), which was likely 'oil of vitriol' or sulfuric acid. The work refers multiple times to Jabir ibn Hayyan's Seventy Books (Liber de septuaginta), one of the few Arabic Jabir works that were translated into Latin. The author of the version attributed to al-Razi also refers to the Liber de septuaginta as his own work, showing that he erroneously believed the Liber de septuaginta to be a work by al-Razi. There are several indications that the anonymous work was an original composition in Latin, although according to one manuscript it was translated by a certain Raymond of Marseilles, meaning that it may also have been a translation from the Arabic. According to Ahmad Y. al-Hassan, three recipes for sulfuric acid occur in an anonymous Garshuni manuscript containing a compilation taken from several authors and dating from before c. 1100 AD. One of them runs as follows:
Judging relationships based on shared characters requires care, since plants may resemble one another through convergent evolution in which characters have arisen independently. Some euphorbias have leafless, rounded bodies adapted to water conservation similar to those of globular cacti, but characters such as the structure of their flowers make it clear that the two groups are not closely related. The cladistic method takes a systematic approach to characters, distinguishing between those that carry no information about shared evolutionary history – such as those evolved separately in different groups (homoplasies) or those left over from ancestors (plesiomorphies) – and derived characters, which have been passed down from innovations in a shared ancestor (apomorphies). Only derived characters, such as the spine-producing areoles of cacti, provide evidence for descent from a common ancestor. The results of cladistic analyses are expressed as cladogram: tree-like diagrams showing the pattern of evolutionary branching and descent. From the 1990s onwards, the predominant approach to constructing phylogenies for living plants has been molecular phylogenetics, which uses molecular characters, particularly DNA sequences, rather than morphological characters like the presence or absence of spines and areoles. The difference is that the genetic code itself is used to decide evolutionary relationships, instead of being used indirectly via the characters it gives rise to.
==== Ligature ==== Ligature (string) is used to ligate and wrap vessels. This is done to organize and have better manipulation of vessels. It is helpful to ligate a vessel when inserting a cannula for injection. Some embalmers use a different color of ligature for the vein than they would the artery. Ligature is also used when closing the mouth. It is used with a needle to weave string through tissue in the mouth. It is channeled through tissue in the bottom lip. It is then pushed through the upper lip into one nasal cavity then pushed through the septum into the other cavity. It is then pushed back through the lip and the embalmer will tie the two ends of string together. Ligature is also used to suture. It can close an incision and be used to help restore trauma like a lesion.
In the 16th century, Paracelsus (1493–1541) described diabetes as a constitutional disease that "irritates the kidneys" and provokes excessive urination. He reported that evaporating urine from a diabetic patient left an excessive residue, which he called "salts". It has, however, been noted that he advised tasting the urine for sweetness in other contexts. In 1674, Thomas Willis made reference to the sweet taste of diabetic urine in Pharmaceutice rationalis. While this reiterated ancient observations from across the Eurasian continent, it is generally understood to be the first explicit reference to sugary diabetic fluids in the modern European context. However, contrary to some claims that the term mellitus was added by Thomas Willis to specify the condition by its glycosuria, the word appears nowhere in his chapter on diabetes. The verifiable statement that may be derived from relevant sources is that Willis elaborated on glycosuria but did not distinguish between different types of diabetes. Notably, Willis disagreed with the common idea that the disorder originated in the kidneys ("Reins"), suggesting instead that it was a "Distemper of the Blood than of the Reins [Kidneys]". He also noted the connection between the condition and certain dietary habits, "chiefly an assiduous and immoderate drinking of Cider, Beer, or sharp Wines". The presence of sugar in the urine (glycosuria) and in the blood (hyperglycemia) was demonstrated through the work of a number of physicians in the late 18th century, including Robert Wyatt (1774) and Matthew Dobson (1776).
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.